Attana´s customer InDex Pharmaceuticals publishes mechanism of action data for their drug candidate cobitolimod
Attana´s customer InDex Pharmaceuticals publishes mechanism of action data for their drug candidate cobitolimod InDex Pharmaceuticals Holding AB (publ) announced on February 25[th] the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC) , shows that the Toll-like receptor 9 (TLR9) agonist